medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2004, Número 2

<< Anterior Siguiente >>

Ann Hepatol 2004; 3 (2)


Experimental models for hepatitis C virus (HCV): New opportunities for combating hepatitis C

Trujillo-Murillo KC, Garza-Rodríguez ML, Martínez-Rodríguez HG, Barrera-Saldaña HA, Bosques-Padilla F, Ramos-Jiménez J, Rivas-Estilla AM

Idioma: Ingles.
Referencias bibliográficas: 76
Paginas: 54-62
Archivo PDF: 118.00 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100.

  2. Montaño-Loza A, Meza-Junco J, Remes-Troche JM. Patogénesis de la infección por virus de hepatitis C. Rev Invest Clin 2001; 53: 561-568.

  3. National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Gastroenterology 2002; 6: 2082-2099.

  4. Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19.

  5. Aguilar-Ramírez JR, Aguirre-García J, Bautista-González H, Baptista-González H, Bosques-Padilla FJ, Campollo-Rivas O, Contreras AM, et al. Consenso Nacional sobre Hepatitis C. Rev Invest Clin 2002; 54: 559-568.

  6. Rivas-Estilla AM, Panduro A. Mecanismos moleculares del virus de la hepatitis C, potenciales blancos terapéuticos. Rev Invest Clin 2003; 55: 51-64.

  7. Méndez-Sánchez N, Aguilar-Ramírez JR, Reyes A, Dehesa M, Juárez A, Castañeda B, Sánchez-Ávila F, et al. Etiology of Liver Cirrhosis in Mexico. Annals of Hepatology 2004; 3: 30-33.

  8. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl Med 2001; 1: 41-52.

  9. Valladares-Álvarez G. Factores de riesgo para la progresión de la infección crónica de la hepatitis viral C. Gastroenterol Perú 2003; 23: 126-133.

  10. World Health Organization. Weekly Epidemiological Record 2002; 77: 41-48.

  11. Choo QL, Kuo GF, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362.

  12. Rivas-Estilla AM, Sánchez LV, Matsui O, Campollo O, Armendáriz-Borunda J, Segura-Ortega JE, Panduro A. Identification of hepatitis C virus (HVC) genotypes in infected patients from the west of Mexico. Hepatology Research 1998; 12: 121-130.

  13. Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernández C, Dehesa-Violante M, Maldonado-Garza H, Pérez-Gómez R, et al. Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial. Annals of Hepatology 2003; 2: 135-139.

  14. Bartenschlager R, Lohmann V. Novel cell culture systems for the hepatitis C virus. Antiviral Research 2001; 52: 1-17.

  15. Feinstone SM, Kapikian AZ, Purceli RH. Hepatitis A: detection by immune electron microscopy of a virus like antigen associated with acute illness. Science 1973; 182: 1026-1028.

  16. He LF, Alling DF, Popkin TF, Shapiro M, Alter HJ, Purcell RH. Determining the size of non-A, non-B hepatitis virus by filtration. J Infect Dis 1987; 156: 636-640.

  17. Bartenschlager R, Lohmann V. Replication of the hepatitis C virus. J Gen Virol 2000; 81; 1631-1648.

  18. Ohba K, Mizokami M, Lau JY, Orito E, Ikeo K, Gojoborit T. Evolutionary relationship of hepatitis C, pesti-, flavi-, plant-, viruses, and newly discovered GB hepatitis agents. FEBS Lett 1996; 378: 232-234.

  19. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line. Science 1999; 285: 110-113.

  20. Puig-Basagoiti F, Sáiz JC. Replicones subgenómicos del virus de la hepatitis C (VHC): nuevas expectativas para la profilaxis y el tratamiento de la hepatitis C. Gastroenterol Hepatol 2001; 24: 506-510.

  21. Drazan KE. Molecular Biology of Hepatitis C Infection. Liver Transplantation 2000; 6: 396-406.

  22. Rosenberg S. Recent advances in the molecular biology of hepatitis C virus. J Mol Biol 2001; 313: 451-464.

  23. Friebe P, Lohmann VF, Krieger NF, Bartenschlager R. Sequences in the 5’ nontranslated region of hepatitis C virus required for RNA replication. J Virol 2001; 75: 12047-12057.

  24. Friebe P, Bartenschlager R. Genetic analysis of sequences in the 3’ nontranslated region of hepatitis C virus that are important for RNA replication. J Virol 2002; 76: 5326-5338.

  25. Tanaka T, Kato N, Cho MJ, Shimotohno K. A novel sequences found at the 3’ terminus of hepatitis C virus genome. Biochem Biophys Res Commun 1995; 215: 744-749.

  26. Kolykhalov AA, Feinstone SM, Rice CM. Identification of a highly conserved sequence element at the 3¢ terminus of hepatitis C virus genome RNA. J Virol 1996; 70: 3363-3371.

  27. Yanagi M, StClaire M, Emerson SU, Purcell RH, Bukh J. In vivo analysis of the 3¢ untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci USA 1999; 96: 2291-2295.

  28. Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Nature 2002; 1: 911-916.

  29. Owsianka AM, Patel AH. Hepatitis C virus core protein interacts with a human DEAD box protein DDX3. Virology 1999; 257: 330: 340.

  30. Marusawa H, Hijikata M, Chiba T, Shimotohmo K. Hepatitis C virus core protein inhibits Fas-and tumor necrosis factor alpha mediated apoptosis via NF-kappa B activation. J Virol 1999; 73: 4713-4720.

  31. Ray RB, Meyer K, Ray R. Hepatitis C virus core protein promotes immortalization of primary human hepatocytes. Virology 2000; 271: 197-204.

  32. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, Eder G, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94: 1200-1205.

  33. Farci P, Shimoda A, Coiana A, Díaz G, Peddis G, Melpolder JC, Strazzera A, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288: 339-344.

  34. Locarnini SA. Mechanism of drug resistance and novel approaches to therapy for chronic hepatitis C. J Gastroenterol Hepatol 2002; 17: S351-S359.

  35. Sanz-Cameno P, Borque MJ, García-Buey L, Moreno-Otero R. Interacción del virus de la hepatitis C con la membrana celular. Gastroenterol Hepatol 2002; 25: 521-525.

  36. Cocquerel L, Kuo CC, Dubuisson J, Levy S. CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J Virol 2003; 19: 10677-10683.

  37. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon inducible protein kinase PKR by HCV E2 protein. Science 1999; 285: 107-110.

  38. Sarrazin C, Kornetzky I, Ruster B, Lee JH, Kronenberger B, Bruch K, Roth WK, et al. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response. Hepatology 2000; 31:1360-1370.

  39. Mihm S, Monazahiam M, Grethe S, Meier V, Thomssen R, Ramadori G. Lack of clinical evidence for involvement of hepatitis C virus interferon alpha sensitivity determining region variability in RNA dependent protein kinase mediated cellular antiviral responses. J Med Virol 2000; 61: 29-36.

  40. Francois C, Duverlie G, Reboulliat D, Khorsi H, Castelain S, Blum HE, Gatignol A, et al. Expression of hepatitis C virus proteins interferes with the antiviral action of interferon independently of PKR mediated control of protein synthesis. J Virol 2000; 74: 5587-5596.

  41. Lesburg CA, Radfar RF, Weber PC. Recent advances in the analysis of HCV NS5B RNA dependent RNA polymerase. Curr Opin Investig Drugs 2000; 1: 289-296.

  42. Rivas-Estilla AM, Svitkin Y, López-Lastra M, Hatzoglou M, Sherker A, Koromilas AE. PKR dependent mechanisms of gene expression from a subgenomic hepatitis C virus clone. J Virol 2002; 76: 10637-10653.

  43. Wang QM, Hockman MA, Staschke KF, Johnson RB, Case KA, Lu J, Parsons S, et al. Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA dependent RNA polymerase. J Virol 2002; 76: 3865-3872.

  44. Pavio N, Lai M. The hepatitis C virus persistente: how to evade the inmune system? J Biosci 2003; 28: 287-304.

  45. Iacovacci S, Sargiacomo M, Parolini I, Ponzetto A, Peschle C, Carloni G. Replication and multiplication of hepatitis C virus genome in human fetal liver cells. Res Virol 1993; 144: 275-279.

  46. Iacovacci S, Manzin A, Barca S, Sargiacomo M, Serafino A, Valli MB, Macioce G, et al. Molecular characterization and dynamics of hepatitis C virus replication in human fetal hepatocytes infected in vitro. Hepatology 1997; 26: 1328-1337.

  47. Ito T, Mukaigawa J, Zuo J, Hirabayashi Y, Mitamura K, Yasui K. Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titles infectious virus. J Gen Virol 1996; 77: 1043-1054.

  48. Lanford RE, Sureau C, Jacob JR, White R, Fuerst TR. Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR. Virology 1994; 202: 606-614.

  49. Rumin S, Berthillon P, Tanaka E, Kiyosawak K, Trabaud MA, Bizollon T, Gouillat C, et al. Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J Gen Virol 1999; 80: 3007-3018.

  50. Cribier B, Schmitt C, Bingen A, Kirn A, Keller F. In vitro infection of peripheral blood mononuclear cells by hepatitis C virus. J Gen Virol 1995; 76: 2485-2491.

  51. Kato N, Ikeda M, Mizutani T, Sugiyamak K, Noguchi M, Hirohashi S, Shimotohno K. Replication of hepatitis C virus in cultured non-neoplastic human hepatocytes. Jpn J Cancer Res 1996; 87: 787-792.

  52. Ikeda M, Kato N, Mizutani T, Sugiyama K, Tanaka K, Shimotohno K. Analysis of the cell tropism of HCV by using in vitro HCV-infected human lymphocytes and hepatocytes. J Hepatol 1997; 27: 445-454.

  53. Ikeda M, Sugiyama K, Mizutani T, Tanaka T, Tanaka K, Sekihara H, Shimotohno K, et al. Human hepatocyte clonal cell lines that support persitent replication of hepatitis C virus. Virus Res 1998; 56: 157-167.

  54. Tawaga M, Kato N, Yokosuka O. Infection of human hepatocyte cell lines with hepatitis C virus in vitro. J Gastroenterol Hepatol 1995; 10: 523-527.

  55. Seipp S, Mueller HM, Pfaff E, Stremmel W, Theilmann L, Goeser T. Establishment of persistent hepatitis C virus infection and replication in vitro. J Gen Virol 1997; 78: 2467-2476.

  56. Clarysse C, Lin L, Crabbe T, Van Pelt JF, Cammack N, Yap SH. HVR1 quasispecies analysis from a long-term culture of hepatitis C virus in Hep G2 derived cells grown in a haemodialysis cartridge. J Viral Hepat 2001; 8: 132-138.

  57. Tsuboi S, Nagamori S, Miyasaki M, Mihara K, Fuyaka K, Teruya K, Kosaka T, et al. Persistence of hepatitis C virus RNA in established human hepatocellular carcinoma cell lines. J Med Virol 1996; 48: 133-140.

  58. Yoshikura H, Hijikata M, Nakajima N, Mizuno K, Rikihisa T, Ueno T, et al. Correlation of in vivo infectivity of hepatitis C virus to in vitro infectivity and to virion properties. Princess Takamatsu Symp 1995; 25: 139-142.

  59. Nakajima N, Hijikata M, Yoshikura H, Shimizu YK. Characterization of long-term cultures of hepatitis C virus. J Virol 1996; 70: 3325-3329.

  60. Shimizu YK, Igarashi H, Kiyohara T, Shapiro M, Wong DC, Purcell RH, Yoshikura H. Infection of a chimpanzee with hepatitis C virus grown in cell culture. J Gen Virol 1998; 79: 1383-1386.

  61. Kato N, Nakazawa T, Mizutani T, Shimotohmo K. Susceptibility of human T-lymphotropic virus type I infected cell line MT-2 to hepatitis C virus infection. Biochem Biophys Res Commun 1995; 206: 863-869.

  62. Mizutani T, Kato N, Saito S, Ikeda M, Sugiyama K, Shimotohno K. Characterization of hepatitis C virus replication in cloned cells obtained from a human T-cell leukemia virus type 1- infected cell line, MT-2. J Virol 1996; 70: 7219-7223.

  63. Shimizu YK, Iwamoto A, Hijikata M, Purcell RH, Yoshikura H. Evidence for in vitro replication of hepatitis C virus genome in a human T-cell line. Proc Natl Acad Sci USA 1992; 89: 5477-5481.

  64. Shimizu YK, Purcell RH, Yoshikura H. Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro. Proc Natl Acad Sci USA 1993; 6037-6041.

  65. Shimizu YK, Yoshikura H. Multicycle infection of hepatitis C virus in cell culture and inhibition by alpha and beta interferons. J Virol 1994; 68: 8406-8408.

  66. Shimizu YK, Feinstone SM, Kohara M, Purcell RH, Yoshikura H. Hepatitis C virus: Detection of infracellular virus particles by electron microscopy. Hepatology 1996; 23: 205-209.

  67. Yoo BJ, Selby MJ, Choe J, Suh BS, Choi SH, Joh JS, Nuoro GJ, et al. Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro transcribed with HCV. J Virol 1995; 69: 32-38.

  68. Dash S, Halim AB, Tsuji H, Hiramatsu N, Gerber MA. Transfection of HepG2 cells with infectious hepatitis C virus genome. Am J Pathol 1997; 151: 363-373.

  69. Mercer D, Schiller D, Elliot J, Douglas DN, Hao C, Rinfret A, Addison WR, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat Med 2001; 7: 927-933.

  70. Pietschmann T, Lohmann V, Rutter G, Kurpanek K, Bartenschlager R. Characterization of cell lines carrying self replicating hepatitis C virus RNAs. J Virol 2001; 75: 1252-1264.

  71. Krieger N, Lohmann V, Bastenschlager R. Enhancement of hepatitis C virus RNA replication by cell culture adaptive mutations. J Virol 2001; 75: 4614-4624.

  72. Lohmann V, Körner F, Doblerzewska A, Bartenschlager R. Mutations in hepatitis C virus RNAs conferring cell culture adaptation. J Virol 2001. 75; 1437-1449.

  73. Ikeda M, Yi M, Lemon SM. Selectable subgenomic and genome length bicistronic RNAs derived from an infectious molecular clone of the HCV-N strain of hepatitis C virus replicate efficiently in cultured Huh7 cells. J Virol 2002; 76: 2997-3006.

  74. Pawlotsky JM. Mechanism of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Research 2003; 59: 1-11.

  75. Beckebaum S, Cicinnati VR, Gerken G. DNA-based immunotherapy: potential for treatment of chronic viral hepatitis?. Rev Med Virol 2002; 12: 297-319.

  76. Lamarre D, Anderson P, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003; 426: 186-189.




2020     |     www.medigraphic.com